Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.

Drug-induced liver injury is the most common cause of market withdrawal of pharmaceuticals, and thus, there is considerable need for better prediction models for DILI early in drug discovery. We present a study involving 223 marketed drugs (51% associated with clinical hepatotoxicity; 49% non-hepatotoxic) to assess the concordance of in vitro bioactivation data with clinical hepatotoxicity and have used these data to develop a decision tree to help reduce late-stage candidate attrition. Data to assess P450 metabolism-dependent inhibition (MDI) for all common drug-metabolizing P450 enzymes were generated for 179 of these compounds, GSH adduct data generated for 190 compounds, covalent binding data obtained for 53 compounds, and clinical dose data obtained for all compounds. Individual data for all 223 compounds are presented here and interrogated to determine what level of an alert to consider termination of a compound. The analysis showed that 76% of drugs with a daily dose of <100 mg were non-hepatotoxic (p < 0.0001). Drugs with a daily dose of ≥100 mg or with GSH adduct formation, marked P450 MDI, or covalent binding ≥200 pmol eq/mg protein tended to be hepatotoxic (∼ 65% in each case). Combining dose with each bioactivation assay increased this association significantly (80-100%, p < 0.0001). These analyses were then used to develop the decision tree and the tree tested using 196 of the compounds with sufficient data (49% hepatotoxic; 51% non-hepatotoxic). The results of these outcome analyses demonstrated the utility of the tree in selectively terminating hepatotoxic compounds early; 45% of the hepatotoxic compounds evaluated using the tree were recommended for termination before candidate selection, whereas only 10% of the non-hepatotoxic compounds were recommended for termination. An independent set of 10 GSK compounds with known clinical hepatotoxicity status were also assessed using the tree, with similar results.

[1]  O. Pelkonen,et al.  Rapid detection and characterization of reactive drug metabolites in vitro using several isotope-labeled trapping agents and ultra-performance liquid chromatography/time-of-flight mass spectrometry. , 2009, Rapid communications in mass spectrometry : RCM.

[2]  G. Mulder,et al.  A rapid, simple in vitro screening test, using [(3)H]glutathione and l-[(35)S]cysteine as trapping agents, to detect reactive intermediates of xenobiotics. , 1988, Toxicology in vitro : an international journal published in association with BIBRA.

[3]  Yan Li,et al.  Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development. , 2011, Chemico-biological interactions.

[4]  A. Kalgutkar,et al.  Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions. , 2007, Current drug metabolism.

[5]  Kuresh Youdim,et al.  Application of PBPK modelling in drug discovery and development at Pfizer , 2012, Xenobiotica; the fate of foreign compounds in biological systems.

[6]  H. Masumoto,et al.  Quantitative assessment of reactive metabolite formation using 35S-labeled glutathione. , 2009, Drug metabolism and pharmacokinetics.

[7]  Lisa M. Gangarosa,et al.  Current Diagnosis and Treatment in Gastroenterology, 2nd edition , 2004 .

[8]  Dominic P. Williams,et al.  Understanding the role of reactive metabolites in drug-induced hepatotoxicity: state of the science. , 2008, Expert opinion on drug metabolism & toxicology.

[9]  Chandan Saha,et al.  Relationship between daily dose of oral medications and idiosyncratic drug‐induced liver injury: Search for signals , 2008, Hepatology.

[10]  O. Chazouilleres,et al.  [Drug-induced hepatotoxicity. The 13th updated edition of the bibliographic database of drug-related liver injuries and responsible drugs]. , 2000, Gastroenterologie clinique et biologique.

[11]  A. Kalgutkar,et al.  Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction. , 2009, Chemical research in toxicology.

[12]  Masashi Yabuki,et al.  Evaluation of the Potential for Drug-Induced Liver Injury Based on in Vitro Covalent Binding to Human Liver Proteins , 2009, Drug Metabolism and Disposition.

[13]  P. Dansette,et al.  Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. , 2005, Current drug metabolism.

[14]  J. Hughes,et al.  Physiochemical drug properties associated with in vivo toxicological outcomes. , 2008, Bioorganic & medicinal chemistry letters.

[15]  P. Matzinger.  Tolerance, danger, and the extended family. , 1994, Annual review of immunology.

[16]  Jinping Gan,et al.  Dansyl glutathione as a trapping agent for the quantitative estimation and identification of reactive metabolites. , 2005, Chemical research in toxicology.

[17]  W. Humphreys,et al.  In vitro screening of 50 highly prescribed drugs for thiol adduct formation--comparison of potential for drug-induced toxicity and extent of adduct formation. , 2009, Chemical research in toxicology.

[18]  Carole E Shardlow,et al.  Utilizing Drug-Drug Interaction Prediction Tools during Drug Development: Enhanced Decision Making Based on Clinical Risk , 2011, Drug Metabolism and Disposition.

[19]  B. Faller,et al.  CYP3A Time-Dependent Inhibition Risk Assessment Validated with 400 Reference Drugs , 2011, Drug Metabolism and Disposition.

[20]  J. Uetrecht.  Idiosyncratic drug reactions: past, present, and future. , 2008, Chemical research in toxicology.

[21]  Nurgun Oktik.  THE DEVELOPMENT OF HIGHER , 2006 .

[22]  A. Stepan,et al.  Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. , 2011, Chemical research in toxicology.

[23]  F. Ballet,et al.  Hepatotoxicity in drug development: detection, significance and solutions. , 1997, Journal of hepatology.

[24]  J. Boyd,et al.  The development of a higher throughput reactive intermediate screening assay incorporating micro-bore liquid chromatography-micro-electrospray ionization-tandem mass spectrometry and glutathione ethyl ester as an in vitro conjugating agent. , 2004, Journal of pharmaceutical and biomedical analysis.

[25]  Kazuhito Shiosakai,et al.  Combination of glutathione trapping and time-dependent inhibition assays as a predictive method drugs generating highly reactive metabolites , 2011 .

[26]  T. Baillie,et al.  Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. , 2004, Chemical research in toxicology.

[27]  Osamu Okazaki,et al.  Predictability of Idiosyncratic Drug Toxicity Risk for Carboxylic Acid-Containing Drugs Based on the Chemical Stability of Acyl Glucuronide , 2010, Drug Metabolism and Disposition.

[28]  Tze Chieh Shiao,et al.  Improved detection of reactive metabolites with a bromine-containing glutathione analog using mass defect and isotope pattern matching. , 2010, Rapid communications in mass spectrometry : RCM.

[29]  R Scott Obach,et al.  Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. , 2008, Chemical research in toxicology.

[30]  P. Jeffrey,et al.  Approaches to assessing drug safety in the discovery phase , 2010 .

[31]  Malcolm Rowland,et al.  Physiologically-based pharmacokinetics in drug development and regulatory science. , 2011, Annual review of pharmacology and toxicology.

[32]  Ian D. Wilson,et al.  Managing the challenge of chemically reactive metabolites in drug development , 2011, Nature Reviews Drug Discovery.

[33]  Jeffrey Ambroso,et al.  An integrated reactive metabolite evaluation approach to assess and reduce safety risk during drug discovery and development. , 2011, Chemico-biological interactions.

[34]  Y. Masubuchi,et al.  Toxicological Significance of Mechanism-Based Inactivation of Cytochrome P450 Enzymes by Drugs , 2007, Critical reviews in toxicology.

[35]  Osamu Okazaki,et al.  A Zone Classification System for Risk Assessment of Idiosyncratic Drug Toxicity Using Daily Dose and Covalent Binding , 2009, Drug Metabolism and Disposition.